In case you’ve missed it, ASX COVID-era tech darling Bigtincan Holdings (ASX:BTH) has received a takeover offer from the ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

Renaissance Technologies took new stakes in Micron Technology (NASDAQ:MU), Eli Lilly (NYSE:LLY), and Cisco Systems ...

Philippe Laffont's Coatue Management released its latest 13F filing. Read here to see its equity ownership moves in Q3.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

A smart beta exchange traded fund, the FlexShares International Quality Dividend ETF (IQDF) debuted on 04/12/2013, and offers broad exposure to the World ETFs category of the market.

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

The Series D financing will support the clinical development of two ADCs.